TY - JOUR
T1 - Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease
AU - Lindquist, Susanne G.
AU - Duno, M
AU - Batbayli, M
AU - Puschmann, A
AU - Braendgaard, H
AU - Mardosiene, S
AU - Svenstrup, K
AU - Pinborg, Lars Hageman
AU - Vestergaard, Kim Fiedler
AU - Hjermind, LE
AU - Stokholm, J
AU - Andersen, Birgitte Bo
AU - Johannsen, P
AU - Nielsen, Jørgen Erik
N1 - G Lindquist1,*, M Duno1, M Batbayli1, A Puschmann2, H Braendgaard3, S Mardosiene4, K Svenstrup4,5,6, LH Pinborg7, K Vestergaard8, LE Hjermind5,6, J Stokholm9, BB Andersen9, P Johannsen9, JE Nielsen5,6
Article first published online: 4 JUL 2012
DOI: 10.1111/j.1399-0004.2012.01903.x
© 2012 John Wiley & Sons A/S
Issue Clinical Genetics
Clinical Genetics
Volume 83, Issue 3, pages 279–283, March 2013
Additional Information(Show All)
How to CiteAuthor InformationPublication History
Author Information
1Department of Clinical Genetics, 4062, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
2Department of Neurology, Skåne University Hospital, Lund, Sweden
3Department of Neurology, Aarhus Sygehus, Aarhus University Hospital, Aarhus, Denmark
4Department of Neurology, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen, Denmark
5Neurogenetics Clinic, Memory Disorders Research Group, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
6Department of Cellular and Molecular Medicine, Section of Neurogenetics, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
7Neurobiology Research Unit, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
8Department of Neurology, Aalborg Hospital, Aarhus University Hospital, Aarhus, Denmark
9Memory Disorders Research Group, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
PY - 2013
Y1 - 2013
N2 - Recently, a hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72 was reported as the cause of chromosome 9p21-linked frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS). We here report the prevalence of the expansion in a hospital-based cohort and associated clinical features indicating a wider clinical spectrum of C9ORF72 disease than previously described. We studied 280 patients previously screened for mutations in genes involved in early onset autosomal dominant inherited dementia disorders. A repeat-primed polymerase chain reaction amplification assay was used to identify pathogenic GGGGCC expansions. As a potential modifier, confirmed cases were further investigated for abnormal CAG expansions in ATXN2. A pathogenic GGGGCC expansion was identified in a total of 14 probands. Three of these presented with atypical clinical features and were previously diagnosed with clinical olivopontocerebellar degeneration (OPCD), atypical Parkinsonian syndrome (APS) and a corticobasal syndrome (CBS). Further, the pathogenic expansion was identified in six FTD patients, four patients with FTD-ALS and one ALS patient. All confirmed cases had normal ATXN2 repeat sizes. Our study widens the clinical spectrum of C9ORF72related disease and confirms the hexanucleotide expansion as a prevalent cause of FTD-ALS disorders. There was no indication of a modifying effect of the ATXN2 gene.
AB - Recently, a hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72 was reported as the cause of chromosome 9p21-linked frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS). We here report the prevalence of the expansion in a hospital-based cohort and associated clinical features indicating a wider clinical spectrum of C9ORF72 disease than previously described. We studied 280 patients previously screened for mutations in genes involved in early onset autosomal dominant inherited dementia disorders. A repeat-primed polymerase chain reaction amplification assay was used to identify pathogenic GGGGCC expansions. As a potential modifier, confirmed cases were further investigated for abnormal CAG expansions in ATXN2. A pathogenic GGGGCC expansion was identified in a total of 14 probands. Three of these presented with atypical clinical features and were previously diagnosed with clinical olivopontocerebellar degeneration (OPCD), atypical Parkinsonian syndrome (APS) and a corticobasal syndrome (CBS). Further, the pathogenic expansion was identified in six FTD patients, four patients with FTD-ALS and one ALS patient. All confirmed cases had normal ATXN2 repeat sizes. Our study widens the clinical spectrum of C9ORF72related disease and confirms the hexanucleotide expansion as a prevalent cause of FTD-ALS disorders. There was no indication of a modifying effect of the ATXN2 gene.
U2 - 10.1111/j.1399-0004.2012.01903.x
DO - 10.1111/j.1399-0004.2012.01903.x
M3 - Journal article
C2 - 22650353
SN - 0009-9163
VL - 83
SP - 279
EP - 283
JO - Clinical Genetics
JF - Clinical Genetics
IS - 3
ER -